Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
Kronos Bio (Nasdaq: KRON) will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at ACR Convergence 2024 in Washington, DC. The presentation, scheduled for November 18, 2024, will showcase how p300 KAT inhibition modulates multiple pro-inflammatory signaling pathways in chronic inflammatory diseases.
The company is exploring the utility of a p300 KAT inhibitor for autoimmune indications, given the role of IRF4 and p300 in immune cells. Kronos Bio remains on track to announce a development candidate for autoimmune diseases by the end of 2024.
The data supports the role of p300 in inflammation and demonstrates that p300 KAT inhibition can modulate pro-inflammatory signaling pathways at well-tolerated in vivo exposures. This approach may address a root cause of inflammation in autoimmune diseases.
Kronos Bio (Nasdaq: KRON) presenterà dati preclinici dal suo programma di inibitori p300 KAT per indicazioni autoimmuni durante l'ACR Convergence 2024 a Washington, DC. La presentazione, programmata per il 18 novembre 2024, mostrerà come l'inibizione di p300 KAT moduli molteplici vie di segnalazione pro-infiammatorie nelle malattie infiammatorie croniche.
L'azienda sta esplorando l'utilità di un inibitore di p300 KAT per indicazioni autoimmuni, data la funzione di IRF4 e p300 nelle cellule immunitarie. Kronos Bio rimane sulla buona strada per annunciare un candidato alla sviluppo per le malattie autoimmuni entro la fine del 2024.
I dati supportano il ruolo di p300 nell'infiammazione e dimostrano che l'inibizione di p300 KAT può modulare le vie di segnalazione pro-infiammatorie a esposizioni in vivo ben tollerate. Questo approccio potrebbe affrontare una causa principale dell'infiammazione nelle malattie autoimmuni.
Kronos Bio (Nasdaq: KRON) presentará datos preclínicos de su programa de inhibidores de p300 KAT para indicaciones autoinmunes en el ACR Convergence 2024 en Washington, DC. La presentación, programada para el 18 de noviembre de 2024, mostrará cómo la inhibición de p300 KAT modula múltiples vías de señalización pro-inflamatorias en enfermedades inflamatorias crónicas.
La empresa está explorando la utilidad de un inhibidor de p300 KAT para indicaciones autoinmunes, dada la función de IRF4 y p300 en las células inmunitarias. Kronos Bio sigue en camino de anunciar un candidato para el desarrollo de enfermedades autoinmunes a finales de 2024.
Los datos respaldan el papel de p300 en la inflamación y demuestran que la inhibición de p300 KAT puede modular las vías de señalización pro-inflamatorias a exposiciones in vivo bien toleradas. Este enfoque podría abordar una causa raíz de la inflamación en enfermedades autoinmunes.
Kronos Bio (Nasdaq: KRON)는 워싱턴 DC에서 열리는 ACR Convergence 2024에서 자가면역 질환을 위한 p300 KAT 억제제 프로그램의 전임상 데이터를 발표할 예정입니다. 2024년 11월 18일로 예정된 발표에서는 p300 KAT 억제가 만성 염증 질환에서 여러 프로-염증 신호 전송 경로를 어떻게 조절하는지를 보여줄 것입니다.
회사는 면역 세포에서 IRF4와 p300의 역할을 감안하여 자가면역 질환에 대한 p300 KAT 억제제의 유용성을 탐색하고 있습니다. Kronos Bio는 2024년 말까지 자가면역 질환을 위한 개발 후보를 발표할 계획입니다.
이 데이터는 염증에서 p300의 역할을 뒷받침하며, p300 KAT 억제가 잘 견딜 수 있는 체내 노출 수준에서 프로-염증 신호 전송 경로를 조절할 수 있음을 나타냅니다. 이 접근법은 자가면역 질환에서 염증의 근본 원인을 해결할 수 있을 것입니다.
Kronos Bio (Nasdaq: KRON) présentera des données précliniques sur son programme d'inhibiteurs de p300 KAT pour des indications auto-immunes lors de l'ACR Convergence 2024 à Washington, DC. La présentation, prévue pour le 18 novembre 2024, mettra en lumière comment l'
L'entreprise explore l'utilité d'un inhibiteur de p300 KAT pour des indications auto-immunes, étant donné le rôle de l'IRF4 et de p300 dans les cellules immunitaires. Kronos Bio reste sur la bonne voie pour annoncer un candidat au développement pour les maladies auto-immunes d'ici la fin 2024.
Les données soutiennent le rôle de p300 dans l'inflammation et démontrent que l'inhibition de p300 KAT peut moduler les voies de signalisation pro-inflammatoires à des niveaux d'exposition in vivo bien tolérés. Cette approche pourrait s'attaquer à une cause racine de l'inflammation dans les maladies auto-immunes.
Kronos Bio (Nasdaq: KRON) wird auf der ACR Convergence 2024 in Washington, DC, präklinische Daten aus seinem p300 KAT-Inhibitorprogramm für autoimmune Indikationen präsentieren. Die am 18. November 2024 geplante Präsentation wird zeigen, wie die Inhibition von p300 KAT multiple pro-inflammatorische Signalwege bei chronisch entzündlichen Erkrankungen moduliert.
Das Unternehmen untersucht die Nützlichkeit eines p300 KAT-Inhibitors für autoimmune Indikationen, da IRF4 und p300 eine Rolle in Immunzellen spielen. Kronos Bio bleibt auf Kurs, bis Ende 2024 einen Entwicklungskandidaten für autoimmune Erkrankungen bekannt zu geben.
Die Daten unterstützen die Rolle von p300 bei Entzündungen und zeigen, dass die Hemmung von p300 KAT pro-inflammatorische Signalwege bei gut verträglichen In-vivo-Expositionen modulieren kann. Dieser Ansatz könnte eine Grundursache von Entzündungen bei autoimmunen Erkrankungen angehen.
- None.
- None.
– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –
– Oral presentation taking place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST –
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at the American College of Rheumatology's annual meeting, ACR Convergence 2024, being held from November 14 to 19, 2024 in Washington, DC.
Kronos Bio is exploring the utility of a p300 KAT inhibitor for autoimmune indications given the role of interferon regulatory factor 4 (IRF4) and p300 in B cells, T cells and other immune cells. The data being presented at the meeting support the role of p300 in inflammation, and the Company remains on track to announce a development candidate for autoimmune diseases by the end of 2024.
"We are leveraging our proprietary discovery engine that decodes complex transcription factor regulatory networks to develop a p300 KAT inhibitor to potentially treat autoimmune diseases. We are highly encouraged by these initial data demonstrating that p300 KAT inhibition can modulate the activity and function of multiple pro-inflammatory signaling pathways in chronic inflammatory diseases at well tolerated in vivo exposures,” said Peter Rahl, Ph.D., vice president of Discovery Biology at Kronos Bio, and corresponding author of the abstract. “The multifaceted and multicellular nature of autoimmune diseases suggests that an orally available therapeutic that selectively inhibits pro-inflammatory transcription in multiple cell types may address a root cause of inflammation.”
Details for the ACR Convergence 2024 abstract are as follows:
Title: p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Presenter: Peter Rahl, Ph.D., Vice President, Discovery Biology
Abstract Number: 2598
Poster Session: Cytokines & Cell Trafficking
Date and Time: Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST
The presentation will be available under the Science & Pipeline section of the Kronos Bio website on November 14, 2024. The abstract can be found on the American College of Rheumatology’s website.
About Kronos Bio
Kronos Bio, Inc. (Nasdaq: KRON) is a clinical-stage company dedicated to developing small molecule therapeutics that address deregulated transcription, a hallmark of cancer and other diseases. Our proprietary discovery engine decodes complex transcription factor regulatory networks to identify druggable cofactors. We screen for and optimize small molecules that target these cofactors in a tumor-specific context. These efforts have yielded a preclinical pipeline along with two internally developed drug candidates. KB-0742 targets CDK9 to address MYC deregulation in solid tumors and KB-9558 targets p300 to address IRF4 dependence in multiple myeloma.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com or follow the Company on LinkedIn.
Forward-Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as “anticipate,” “believe,” “could,” “expect,” “plan,” “will,” “may,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, Kronos Bio’s ability to leverage its proprietary discovery engine to develop a development candidate to potentially treat autoimmune diseases; the timing of an announcement of a development candidate for autoimmune diseases; potential programs in Kronos Bio’s pipeline; the potential of Kronos Bio’s product candidates, pipeline and its proprietary discovery engine; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: changes in the macroeconomic environment or competitive landscape that impact Kronos Bio’s business; whether Kronos Bio will be able to progress its preclinical pipeline on the timelines anticipated, including due to risks inherent in the development of novel therapeutics; the risk that results of preclinical studies, early clinical trials (including preliminary results) and pharmacokinetic modeling are not necessarily predictive of future results; and risks associated with the sufficiency of Kronos Bio’s cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 8, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
FAQ
What is Kronos Bio presenting at ACR Convergence 2024?
When and where is Kronos Bio's presentation at ACR Convergence 2024?
What is the potential impact of Kronos Bio's p300 KAT inhibitor research?
When does Kronos Bio (KRON) expect to announce a development candidate for autoimmune diseases?
